Search

Robert W Gracy

from Helotes, TX
Age ~82

Robert Gracy Phones & Addresses

  • 12334 Montel, Helotes, TX 78023 (817) 832-5399
  • Lipan, TX
  • Pottsboro, TX
  • Denton, TX
  • 3417 Bellaire Park Ct, Fort Worth, TX 76109
  • Three Springs, PA

Work

Position: President and chief executive officer

Resumes

Resumes

Robert Gracy Photo 1

President And Chief Executive Officer

View page
Location:
12334 Montel, Helotes, TX 78023
Work:

President and Chief Executive Officer

Business Records

Name / Title
Company / Classification
Phones & Addresses
Robert Gracy
Director
BIODFW
Nonclassifiable Establishments
4100 Alpha Rd STE 215, Dallas, TX 75244
901 Main St, Dallas, TX 75202
Robert Gracy
TEXAS BIOLOGICAL AND AGRO-DEFENSE CONSORTIUM
14785 Omicron Dr STE 101, San Antonio, TX 78245
14815 Omicron Dr SUITE 100, San Antonio, TX 78245

Publications

Us Patents

Non-Contracting Tissue Equivalent

View page
US Patent:
6471958, Oct 29, 2002
Filed:
Feb 1, 2001
Appl. No.:
09/775843
Inventors:
S. Dan Dimitrijevich - Bedford TX
Robert W. Gracy - Fort Worth TX
Assignee:
University of North Texas Health Science Center - Fort Worth TX
International Classification:
C12N 508
US Classification:
424 937, 435325, 435371, 435373, 435395, 435397
Abstract:
The present invention provides a non-contracting tissue equivalent comprising at least one cellular component and at least one non-cellular component. The tissue equivalent closely resembles normal tissue in being substantially non-contracting. In addition, the non-contracting tissue equivalent is translucent, allowing direct visual observation of the different layers of cells in the tissue equivalent. The non-contracting tissue equivalent is useful for a variety of complete tissue replacements including skin and cornea. The non-contracting tissue equivalent is useful for in vitro testing, evaluation and screening of potential pharmaceuticals or consumer products, production of biocompatible clinical products for tissue replacement and augmentation, and research studies on fundamental aspects of tissue structure and function. The capability for direct visual observation of layers of cells permits manual or automated assessment of important biological parameters of the tissue, including cell viability, proliferation, motility, and differentiation.

Treatment Of Osteoarthritis By Administering Poly-N-Acetyl-D-Glucosamine

View page
US Patent:
20010014671, Aug 16, 2001
Filed:
Feb 9, 2001
Appl. No.:
09/780237
Inventors:
William Sherman - Hendersonville NC, US
Robert Gracy - Fort Worth TX, US
Assignee:
Lescarden, Inc.
International Classification:
A61K031/715
US Classification:
514/062000, 514/054000
Abstract:
The methods of the present invention relate to administering to a mammal afflicted with osteoarthritis an effective amount of poly-N-acetyl-D-glucosamine (poly-NAG), partially depolimerized poly-NAG, pharmaceutically acceptable salts of poly-NAG, or mixtures thereof, to treat osteoarthritis and/or alleviate the symptoms of osteoarthritis such as pain, joint tenderness and swelling and impaired joint mobility. The present invention also comprises solid and liquid pharmaceutical dosage forms comprising poly-NAG, its pharmaceutically acceptable salts and mixtures thereof. These dosage forms may be administered orally and by-injection to treat osteoarthritis and/or alleviate the symptoms thereof.

Treatment Of Osteoarthritis By Administering Poly-N-Acetyl-D-Glucosamine

View page
US Patent:
61178519, Sep 12, 2000
Filed:
Dec 12, 1997
Appl. No.:
8/990161
Inventors:
William T. Sherman - Hendersonville NC
Robert W. Gracy - Fort Worth TX
Assignee:
Lescarden Inc. - New York NY
International Classification:
A61K 3170
US Classification:
514 62
Abstract:
The methods of the present invention relate to administering to a mammal afflicted with osteoarthritis an effective amount of poly-N-acetyl-D-glucosamine (poly-NAG), partially depolimerized poly-NAG, pharmaceutically acceptable salts of poly-NAG, or mixtures thereof, to treat osteoarthritis and/or alleviate the symptoms of osteoarthritis such as pain, joint tenderness and swelling and impaired joint mobility. The present invention also comprises solid and liquid pharmaceutical dosage forms comprising poly-NAG, its pharmaceutically acceptable salts and mixtures thereof. These dosage forms may be administered orally and by-injection to treat osteoarthritis and/or alleviate the symptoms thereof.
Robert W Gracy from Helotes, TX, age ~82 Get Report